← Back to Search

N/A

Dextromethorphan for Fibromyalgia

Phase 2
Waitlist Available
Led By Jarred W Younger, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 weeks
Awards & highlights

Study Summary

This trial will test whether Dextromethorphan, a drug found in cough suppressants, can reduce pain for people with Fibromyalgia.

Eligible Conditions
  • Fibromyalgia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Daily Self-reported Pain Severity
Secondary outcome measures
Daily Self-reported Physical Activity
Patient Global Impression of Change

Side effects data

From 2013 Phase 4 trial • 45 Patients • NCT01766050
14%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
Inje Cocktail Alone and Inje Cocktail Plus Belatacept

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DextromethorphanExperimental Treatment1 Intervention
Participant will take one dextromethorphan 10mg capsule in the morning and at night.
Group II: PlaceboPlacebo Group1 Intervention
Participants will take one placebo capsule in the morning and at night.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dextromethorphan
FDA approved

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,594 Previous Clinical Trials
2,282,442 Total Patients Enrolled
6 Trials studying Fibromyalgia
40,315 Patients Enrolled for Fibromyalgia
Jarred W Younger, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham
1 Previous Clinical Trials
39 Total Patients Enrolled
~4 spots leftby Jun 2025